8 weeks of 25 g/day of milled chia supplemented-isocaloric diet

Non-Alcoholic Fatty Liver Disease

Dietary Modification

8 weeks of an isocaloric diet supplemented with 25 g/day of milled chia

Milled chia seeds

Chia Supplementation and Non Alcoholic Fatty Liver Disease

Effect of a Chia Supplemented Diet (Salvia Hispanica) on the Cardiometabolic Risk Profile in Patients With NAFLD (Non Alcoholic Fatty Liver Disease)

To assess the effect of 25 g/day of milled chia in 25 patients with NAFLD.Improvement of LSAI (liver spleen attenuation index) measured by computed tomography In a single-arm experimental design study

Increase in Alpha linolenic acid with chia supplemented diet. Measured by gas chromatography.

Improvement of lipid parameters (total colesterol, LDL-C, triglycerides, HDL-C) including free fatty acids

Aida Medina Urrutia

Medical sience investigator

Instituto Nacional de Cardiologia Ignacio Chavez

Spinal Cord Injuries

Osteoporosis

Metabolic Syndrome

Rosuvastatin Calcium

Placebo Oral Tablet

Coenzyme Q10

1250mg Calcium Carbonate, daily for 12 months

Calcium Carbonate

Vitamin D

University Of Miami Miller School of Medicine

University Health Network - Toronto Rehab Lyndhurst Centre

Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk

The Efficacy and Safety of Rosuvastatin for Modifying Bone Mass and Cardiometabolic Disease Outcomes

Dual Xray Absorptiometry (DXA) Assessment of areal bone mineral density (aBMD) of the knee region

Peripheral Quantitative Computed Tomography (pQCT) assessment - Toronto Site Only

High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) assessment - Toronto Site Only

Whole Body DXA assessment of body composition

Assessment of Aortic Pulse Wave Velocity (aPWV)

Dr. B. Catharine. Craven

Clinician Scientist/Principal Investigator

The Craig H. Neilsen Foundation

Toronto Rehabilitation Institute

University Health Network, Toronto

University of Miami

Rick Hansen Institute

Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART

HIV-associated Hypertriglyceridemia

HIV-associated Hypercholesterolemia

HIV-associated Inflammatory State

Multicenter, prospective, double-blind, randomized study of 48 weeks duration, in which the effect of 4 g daily of DHA vs 4 g daily of placebo (oleic acid) are studied on modulation of the Triglycerides and other lipids in patients with HIV infection under HAART treatment.

Hospital de la Santa Creu i Sant Pau

Effect of DHA on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in HIV Patients Under HAART.

Double-blind, Placebo-controlled, Randomized 48 Weeks of Duration Study. The Effect of the Administration of Docosahexaenoic Acid on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in Patients With HIV Infection Under High Activity Antiretroviral Treatment

Fasting serum levels of LDL, HDL, and non-HDL cholesterol

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Hospital Clinic of Barcelona

University of Barcelona

Obeticholic acid 25 mg/day in three weeks

Obeticholic acid 25 mg/day matching placebo in three weeks

Obesity

Gallstones

Obeticholic acid

Placebo

Hanns-Ulrich Marschall

Obeticholic Acid in Bariatric and Gallstone Disease

Effects of Obeticholic Acid on Hepatic Fatty Acid/Triglyceride Metabolism and Hepatobiliary Detoxification/Elimination in Morbidly Obese and Gallstone Patients

Primary endpoints
relative changes in markers for insulin resistance
relative changes in FA and TG
relative changes in hepatic and adipose tissue lipase expression and activity
relative changes in hepatic apical transport proteins ABCG5/8, BSEP, MDR3, MRP2
relative changes in hepatic ER stress markers

Secondary endpoints
relative changes in m RNA expression levels of genes listed under 3.ix
relative changes in hepatic basolateral transport proteins listed under 3.x
relative change in serum bile acids as listed under 3.xii, including INT-747
relative changes in biliary lipids (cholesterol, phospholipids, bile acids)
relative change in plasma 7α-hydroxy-4-cholesten-3-one and FGF-19
relative changes in total cholesterol, LDL-C, HDL-C, Apo A1, Apo B, in Lp(A)

arnold-chiari malformation/triglyceride

Chia Supplementation and Non Alcoholic Fatty Liver Disease

Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk

Effect of DHA on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in HIV Patients Under HAART.

Obeticholic Acid in Bariatric and Gallstone Disease

De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap